Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 12/20 | 0.62 |
| ▸ | ITGA4 | P13612 | 12/20 | 0.62 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.37 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2434649 | 1.00 | ITGB1 (0.62) | ITGB1ITGA4CSNK1DL3MBTL1TP53 | |
| SCHEMBL2433608 | 0.94 | ITGB1 (0.54) | ITGB1ITGA4CSNK1DL3MBTL1SMN1; SMN2 | |
| SCHEMBL2433605 | 0.94 | ITGB1 (0.54) | ITGB1ITGA4CSNK1DL3MBTL1SMN1; SMN2 | |
| SCHEMBL2437593 | 0.94 | ITGB1 (0.61) | ITGB1ITGA4CSNK1DSMN1; SMN2RIPK1 | |
| SCHEMBL2437591 | 0.94 | ITGB1 (0.61) | ITGB1ITGA4CSNK1DSMN1; SMN2RIPK1 | |
| SCHEMBL2430244 | 0.93 | ITGB1 (0.62) | ITGB1ITGA4CSNK1DRIPK1RIPK3 | |
| SCHEMBL2430247 | 0.93 | ITGB1 (0.62) | ITGB1ITGA4CSNK1DRIPK1RIPK3 | |
| SCHEMBL2429216 | 0.91 | ITGB1 (0.61) | ITGB1ITGA4 | |
| SCHEMBL2429220 | 0.91 | ITGB1 (0.61) | ITGB1ITGA4 | |
| SCHEMBL5362146 | 0.89 | ITGB1 (0.62) | ITGB1ITGA4RIPK1RIPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | ITGB1 5/4885ITGA4 4/4885CSNK1D 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.